- Home
- DDS vs MDGL Comparison
DDS vs MDGL Comparison
Compare DDS & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DDS
- MDGL
- Stock Information
- Founded
- DDS 1938
- MDGL 2011
- Country
- DDS United States
- MDGL United States
- Employees
- DDS N/A
- MDGL N/A
- Industry
- DDS Department/Specialty Retail Stores
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- DDS Consumer Discretionary
- MDGL Health Care
- Exchange
- DDS Nasdaq
- MDGL Nasdaq
- Market Cap
- DDS 9.2B
- MDGL 9.6B
- IPO Year
- DDS N/A
- MDGL N/A
- Fundamental
- Price
- DDS $605.23
- MDGL $420.19
- Analyst Decision
- DDS Sell
- MDGL Strong Buy
- Analyst Count
- DDS 3
- MDGL 12
- Target Price
- DDS $394.33
- MDGL $521.09
- AVG Volume (30 Days)
- DDS 92.1K
- MDGL 270.5K
- Earning Date
- DDS 11-13-2025
- MDGL 11-04-2025
- Dividend Yield
- DDS 4.29%
- MDGL N/A
- EPS Growth
- DDS N/A
- MDGL N/A
- EPS
- DDS 36.31
- MDGL N/A
- Revenue
- DDS $6,585,750,000.00
- MDGL $515,547,000.00
- Revenue This Year
- DDS N/A
- MDGL $394.38
- Revenue Next Year
- DDS N/A
- MDGL $64.73
- P/E Ratio
- DDS $16.70
- MDGL N/A
- Revenue Growth
- DDS N/A
- MDGL 3421.98
- 52 Week Low
- DDS $282.24
- MDGL $201.22
- 52 Week High
- DDS $637.73
- MDGL $463.63
- Technical
- Relative Strength Index (RSI)
- DDS 53.38
- MDGL 44.64
- Support Level
- DDS $589.15
- MDGL $413.82
- Resistance Level
- DDS $616.96
- MDGL $445.06
- Average True Range (ATR)
- DDS 21.51
- MDGL 16.35
- MACD
- DDS -2.91
- MDGL -3.80
- Stochastic Oscillator
- DDS 49.13
- MDGL 17.11
About DDS Dillard's Inc.
Dillard's Inc is an American fashion apparel, cosmetics, and home furnishings retailer. Its stores offer a large variety of merchandise and feature products from both national and exclusive brand sources. The company also operates a general contracting construction company, CDI Contractors. CDI Contractors' business includes constructing and remodelling stores for Dillards. The merchandise selections include exclusive brand merchandise such as Antonio Melani, Gianni Bini, Daniel Cremieux, Roundtree & Yorke, and private-label merchandise, among others. The company operates in two business segments; Retail Operations and Construction. The Retail Operations segment generates maximum revenue for the company.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.